Smart Inhalers Market 2024-2030: Trends, Opportunities, and Challenges

The global smart inhalers market size was estimated at USD 15.4 billion in 2023 and is expected to expand at a CAGR of 19.4% from 2024 to 2030. 

The rising prevalence of chronic respiratory diseases (CRDs) globally, the development of technologically advanced products, and the growing adoption of digital solutions in the healthcare sector are expected to contribute to the market's growth. According to estimates from the American Lung Association in 2022, 11.7 million people, or 4.6% of adults, reported a diagnosis of COPD, including chronic bronchitis and emphysema. In addition, the WHO estimates that potentially fatal respiratory diseases, including COPD, lung cancer, and tuberculosis, will account for about one in five deaths worldwide by 2030.

Gather more insights about the market drivers, restrains and growth of the Smart Inhalers Market

The increasing focus on developing smart inhalers and a rise in initiatives by key market players for R&D efforts drive the demand for smart inhalers. In addition, more companies are integrating digital technologies into their product offerings to enhance medication effectiveness and the management of asthma and COPD. For instance, in April 2022, Aptar Pharma, a market player, introduced HeroTracker Sense, a chronic respiratory digital e-health solution that converts a conventional metered dose inhaler into a smart inhaler.

Furthermore, various research studies highlighting the benefits of adopting smart inhalers, such as assisting patients in treatment adherence and controlling symptoms, are also contributing to the market growth. For instance, a 2020 Cleveland Clinic study discovered that patients with COPD using Propeller company’s smart inhalers had a noticeably lower risk of being admitted to the hospital, with a nearly 35% drop in visits compared to the prior year.

In addition, the COVID-19 pandemic significantly disrupted supply chains globally, leading to inventory shortages. This disruption complicated regulatory, clinical testing, and post-approval procedures during the pandemic. However, post-pandemic market growth is anticipated owing to the increasing adoption of connected medical devices among healthcare providers to enhance patient care.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global X-ray systems market size was estimated at USD 8.13 billion in 2023 and is projected to grow at a CAGR of 3.26% from 2024 to 2030. 

• The global molecular imaging market size was estimated at USD 8.45 billion in 2023 and is expected to grow at a CAGR of 4.52% from 2024 to 2030. 

Smart Inhalers Market Report Segmentation

Grand View Research has segmented the global smart inhalers market report based on type, indication, distribution channel, end use and region.

Type Outlook (Revenue, USD Million, 2018 - 2030)

• Dry Powdered Inhalers (DPIs)

• Metered Dose Inhalers (MDIs)

Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Asthma

• COPD

• Others

Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Homecare Settings

• Others

Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Russia

• Asia Pacific

o Japan

o China

o India

o Australia

o South Korea

o Singapore

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa

o Saudi Arabia

o South Africa

o UAE

Key Companies profiled:

• Presspart Verwaltungs GmbH.

• Personal Air Quality Systems Pvt Ltd

• COHERO Health Inc. (AptarGroup, Inc.)

• Cognita Labs

• adherium

• Amiko Digital Health Limited.

• Teva Pharmaceuticals Industries Ltd.

• Propeller Health (ResMed)

• Novartis AG

• Pneuma Respiratory Inc.

• 3M

• AireHealth, Inc.

• FindAir Sp. z o.o

Key Smart Inhalers Company Insights

Key players in the respiratory market are employing strategies such as new product development, partnerships, and mergers & acquisitions to expand their market share. Notable companies include COHERO Health Inc. (AptarGroup, Inc.), Adherium, Propeller Health (ResMed), Novartis AG, Teva Pharmaceuticals Industries Ltd., and 3M. These players are utilizing various approaches to gain a competitive edge.

For instance, in August 2022, Adherium Limited, known for its respiratory eHealth and data management solutions, partnered with Trudell Medical Limited. This collaboration aims to serve COPD patients in the U.S. by combining Trudell's U.S. operations, Monaghan Medical, and Aetonix's aTouchAway platform with Adherium's Hailie sensors. The goal of this partnership is to evaluate COPD patients post-hospital discharge, reduce readmissions, and enhance patient outcomes.

Recent Developments

• In April 2024, Adherium announced that it received FDA clearance for the use of its Hailie Smartinhaler with AstraZeneca’s Breztri and Airsupra inhalation devices. This clearance introduces real-time insights through data collection into inhaler technique and medication usage.

• In September 2021, BreatheSuite received FDA clearance for its device, BreatheSuite Metered-Dose Inhaler (MDI) V1. This device turns the MDIs into smart inhalers by providing feedback and monitoring the inhaler techniques and adherence for people with COPD and asthma.

• In May 2020, AstraZeneca announced a partnership with Propeller Health to add smart features to its Symbicort inhaler, digitizing the treatment of COPD and asthma and increasing medication adherence.

• For instance, in April 2020, Adherium Limited partnered with Planet Innovation to develop software and hardware for respiratory devices. This partnership strengthened Adherium's presence in COPD and asthma management by offering sensors created to provide the physiological data required to enable physician monitoring.

Order a free sample PDF of the Smart Inhalers Market Intelligence Study, published by Grand View Research.